Streetbeat News

Regulatory

DFLI

Dragonfly Energy's shares are trading higher following the announcement of a new US patent, which supports the company's continued momentum towards domestic non-flammable lithium battery production.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:29 pm

HEPA

Hepion Pharmaceuticals (NASDAQ:HEPA) has received clearance from the Data and Safety Monitoring Board (DSMB) to proceed without modification in its Phase 2b ASCEND-NASH trial of Rencofilstat. The trial is on track to complete enrollment in Q1 2024, and initial subjects are approaching the later stages of the 12-month trial.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:22 pm

VGK

The European Central Bank (ECB) has raised three interest rates by 25 basis points, according to Reuters. This move could impact European markets and related ETFs such as VGK.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:18 pm

VGK

The European Central Bank (ECB) has raised the interest rate on its marginal lending facility to 4.25%, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:17 pm

VGK

The European Central Bank (ECB) has raised its benchmark refinancing rate to 4.00%, according to Reuters. This may impact the Vanguard FTSE Europe ETF (VGK).

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:16 pm

AAVEUSD

USDTUSD

Tether's stablecoin USDT experienced a temporary de-pegging as the Curve 3Pool became imbalanced, with USDT's balance surging to over 70%. This resulted in USDT trading at around $0.997. The imbalance may be due to direct attacks on Tether or whales attempting to harm Curve positions by shorting USDT on AAVE.

Portfolio Pulse from Murtuza Merchant

June 15, 2023 | 12:15 pm

FBIO

Helocyte, a subsidiary of Fortress Biotech, announced that the National Cancer Institute has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:04 pm

GLYC

GlycoMimetics announced that the FDA has cleared the addition of a time-based final analysis to the pivotal Phase 3 study of Uproleselan in relapsed/refractory acute myeloid leukemia. The final analysis will be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date, with topline results expected by the end of Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 12:03 pm

CKHUY

VOD

Vodafone Group and CK Hutchison Holdings' UK telecommunication businesses merger is under scrutiny by the UK's Competition and Markets Authority (CMA). The merger would result in Vodafone owning 51% and CKHGT owning 49% of the combined business. Approval is needed under the National Security and Investment Act, posing a risk to the deal.

Portfolio Pulse from Lekha Gupta

June 15, 2023 | 11:56 am

MRSN

Mersana Therapeutics' shares are trading lower after the FDA issued a partial clinical hold, pausing new patient enrollment in the company's UP-NEXT and UPGRADE-A ovarian cancer trials.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:49 am